oncoReveal® CDx
Pan-Cancer Solid Tumor IVD
FDA Approved
oncoReveal™ CDx is an FDA PMA-approved, NGS-based companion diagnostic (CDx) kit providing comprehensive genomic results, covering 22 clinically relevant genes. oncoReveal CDx has a single-tube workflow that can be performed by any clinical laboratory, providing sample-to-clinical report in less than 48 hours.
oncoReveal CDx has been clinically and analytically validated across all major solid tumors. The assay kit is designed to provide clinically actionable information — both to consider appropriate CDx therapies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and to aid in the identification of other clinically significant genomic alterations for patients with solid tumors.
Table 1: Approved Companion Diagnostic and Tumor-Profiling Indications
| ABL1 | BRAF | CEBPA | ETV6 | HRAS | KDM6A | NPM1 | PTEN | SMC1A | TP53 |
| ANKRD26 | CALR | CSF3R | EZH2 | IDH1 | KIT | NRAS | PTPN11 | SMC3 | U2AF1 |
| ASXL1 | CBL | CUX1 | FLT3 | IDH2 | KMT2A | PDGFRA | RAD21 | SRSF2 | WT1 |
| ATRX | CBLB | DDX41 | GATA1 | IKZF1 | KRAS | PHF6 | RUNX1 | STAG1 | ZRSR2 |
| BCOR | CBLC | DNMT3A | GATA2 | JAK2 | MPL | PIGA | SETBP1 | STAG2 | |
| BCORL1 | CDKN2A | ETNK1 | GNAS | JAK3 | NF1 | PPM1D | SF3B1 | TET2 |
| ABL1 | DDX41 | KDM6A | RUNX1 |
| ANKRD26 | DNMT3A | KIT | SETBP1 |
| ASXL1 | ETNK1 | KMT2A | SF3B1 |
| ATRX | ETV6 | KRAS | SMC1A |
| BCOR | EZH2 | MPL | SMC3 |
| BCORL1 | FLT3 | NF1 | SRSF2 |
| BRAF | GATA1 | NPM1 | STAG1 |
| CALR | GATA2 | NRAS | STAG2 |
| CBL | GNAS | PDGFRA | TET2 |
| CBLB | HRAS | PHF6 | TP53 |
| CBLC | IDH1 | PIGA | U2AF1 |
| CDKN2A | IDH2 | PPM1D | WT1 |
| CEBPA | IKZF1 | PTEN | ZRSR2 |
| CSF3R | JAK2 | PTPN11 | |
| CUX1 | JAK3 | RAD21 |
Simple NGS Library Prep Workflow
Maintain control of samples and results with single-tube, tiled amplification that can be performed in-house by any NGS labSensitive and Robust Chemistry
Achieve variant detection as low as 1% VAF* even with limited DNA input or poor sample qualityReduced Fully-Loaded Lab Costs
Improve lab efficiency and reduce “no calls”, repeat testing, and difficult interpretation decisions*VAF, variant allele frequency
For Research Use Only. Not for use in diagnostic procedures..
Panel Specifications*
| Enrichment chemistry | Multiplex PCR using tiled amplicons |
| Number of pools | 1 pool |
| Number of genes/amplicons | 58/766 |
| Number of targets | Full CDS coverage of 18 genes, hotspots in 40 additional genes, FLT3 ITDs; 107.9kb total size |
| Variant types | SNVs, indels, ITD (internal tandem duplicates) |
| Average amplicon size | 217bp |
| Recommended DNA input range | 20ng to 60ng (20ng recommended) |
| Sample types | DNA from whole blood, PBMCs |
| Mapping rate | 99.6% ± 0.2% |
| % on-target aligned reads | 92.0% ± 5.3% |
| Coverage uniformity (% targets with >0.2X mean coverage) | 96.8% ± 1.0% |
| Recommended Reads Per Sample | ~4 million paired-end reads |
| Total assay time (from DNA to sequencer) | <8 hours |
Ordering Information
Select the panel and one of the index kit options listed below.
| Panel | Part Number |
|---|---|
| oncoReveal® Myeloid Panel (24 reactions) | HDA-MY-1001-24 |
| Pillar Index Kit Options | Reactions | Part Number |
|---|---|---|
| Pillar Custom Index Primers Kit A | 32 Combinations, 96 Reactions | IDX-PI-1001-96 |
| Pillar Custom Index Primers Kit D | 96 Combinations, 192 Reactions | IDX-PI-1004-192 |
User Guide
Myeloid Panel